Búsqueda | Portal de Búsqueda de la BVS Ecuador

1.

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders.

Pagliuca, Simona; Gurnari, Carmelo; Awada, Hassan; Kishtagari, Ashwin; Kongkiatkamon, Sunisa; Terkawi, Laila; Zawit, Misam; Guan, Yihong; LaFramboise, Thomas; Jha, Babal K; Patel, Bhumika J; Hamilton, Betty K; Majhail, Navneet S; Lundgren, Sofie; Mustjoki, Satu; Saunthararajah, Yogen; Visconte, Valeria; Chan, Timothy A; Yang, Chao-Yie; Lenz, Tobias L; Maciejewski, Jaroslaw P.

Blood ; 138(26): 2781-2798, 2021 12 30.

Artículo en Inglés | MEDLINE | ID: mdl-34748628

2.

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.

Awada, Hassan; Durmaz, Arda; Gurnari, Carmelo; Kishtagari, Ashwin; Meggendorfer, Manja; Kerr, Cassandra M; Kuzmanovic, Teodora; Durrani, Jibran; Shreve, Jacob; Nagata, Yasunobu; Radivoyevitch, Tomas; Advani, Anjali S; Ravandi, Farhad; Carraway, Hetty E; Nazha, Aziz; Haferlach, Claudia; Saunthararajah, Yogen; Scott, Jacob; Visconte, Valeria; Kantarjian, Hagop; Kadia, Tapan; Sekeres, Mikkael A; Haferlach, Torsten; Maciejewski, Jaroslaw P.

Blood ; 138(19): 1885-1895, 2021 11 11.

Artículo en Inglés | MEDLINE | ID: mdl-34075412

3.

Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.

Lau, Henry; Woost, Philip G; Friedrich, Ute; Clausen, Wan Hui Ong; Jacobberger, James W; Saunthararajah, Yogen.

Eur J Haematol ; 111(3): 345-355, 2023 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-37417197

4.

Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.

von Knebel Doeberitz, Nikolaus; Paech, Daniel; Sturm, Dominik; Pusch, Stefan; Turcan, Sevin; Saunthararajah, Yogen.

Int J Cancer ; 151(9): 1431-1446, 2022 11 01.

Artículo en Inglés | MEDLINE | ID: mdl-35603902

5.

OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug.

Banerjee, Shuvojit; Gusho, Elona; Gaughan, Christina; Dong, Beihua; Gu, Xiaorong; Holvey-Bates, Elise; Talukdar, Manisha; Li, Yize; Weiss, Susan R; Sicheri, Frank; Saunthararajah, Yogen; Stark, George R; Silverman, Robert H.

Proc Natl Acad Sci U S A ; 116(11): 5071-5076, 2019 03 12.

Artículo en Inglés | MEDLINE | ID: mdl-30814222

6.

Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.

Awada, Hassan; Mahfouz, Reda Z; Kishtagari, Ashwin; Kuzmanovic, Teodora; Durrani, Jibran; Kerr, Cassandra M; Patel, Bhumika J; Visconte, Valeria; Radivoyevitch, Tomas; Lichtin, Alan; Carraway, Hetty E; Maciejewski, Jaroslaw P; Saunthararajah, Yogen.

Br J Haematol ; 188(6): 924-929, 2020 03.

Artículo en Inglés | MEDLINE | ID: mdl-31736067

7.

Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.

Ueda, Masumi; El-Jurdi, Najla; Cooper, Brenda; Caimi, Paolo; Baer, Linda; Kolk, Merle; Brister, Lauren; Wald, David N; Otegbeye, Folashade; Lazarus, Hillard M; Sandmaier, Brenda M; William, Basem; Saunthararajah, Yogen; Woost, Philip; Jacobberger, James W; de Lima, Marcos.

Biol Blood Marrow Transplant ; 25(6): 1122-1127, 2019 06.

Artículo en Inglés | MEDLINE | ID: mdl-30599207

8.

Targeting sickle cell disease root-cause pathophysiology with small molecules.

Saunthararajah, Yogen.

Haematologica ; 104(9): 1720-1730, 2019 09.

Artículo en Inglés | MEDLINE | ID: mdl-31399526

9.

ß-Hemoglobinopathies lead the way.

Saunthararajah, Yogen.

Blood ; 137(12): 1567-1569, 2021 03 25.

Artículo en Inglés | MEDLINE | ID: mdl-33764430

10.

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Molokie, Robert; Lavelle, Donald; Gowhari, Michel; Pacini, Michael; Krauz, Lani; Hassan, Johara; Ibanez, Vinzon; Ruiz, Maria A; Ng, Kwok Peng; Woost, Philip; Radivoyevitch, Tomas; Pacelli, Daisy; Fada, Sherry; Rump, Matthew; Hsieh, Matthew; Tisdale, John F; Jacobberger, James; Phelps, Mitch; Engel, James Douglas; Saraf, Santhosh; Hsu, Lewis L; Gordeuk, Victor; DeSimone, Joseph; Saunthararajah, Yogen.

PLoS Med ; 14(9): e1002382, 2017 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-28880867

11.

The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

Cui, Shuaiying; Lim, Kim-Chew; Shi, Lihong; Lee, Mary; Jearawiriyapaisarn, Natee; Myers, Greggory; Campbell, Andrew; Harro, David; Iwase, Shigeki; Trievel, Raymond C; Rivers, Angela; DeSimone, Joseph; Lavelle, Donald; Saunthararajah, Yogen; Engel, James Douglas.

Blood ; 126(3): 386-96, 2015 Jul 16.

Artículo en Inglés | MEDLINE | ID: mdl-26031919

12.

The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).

Rivers, Angela; Vaitkus, Kestis; Ibanez, Vinzon; Ruiz, Maria Armila; Jagadeeswaran, Ramasamy; Saunthararajah, Yogen; Cui, Shuaiying; Engel, James D; DeSimone, Joseph; Lavelle, Donald.

Haematologica ; 101(6): 688-97, 2016 06.

Artículo en Inglés | MEDLINE | ID: mdl-26858356

13.

Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Gu, Xiaorong; Hu, Zhenbo; Ebrahem, Quteba; Crabb, John S; Mahfouz, Reda Z; Radivoyevitch, Tomas; Crabb, John W; Saunthararajah, Yogen.

J Biol Chem ; 289(21): 14881-95, 2014 May 23.

Artículo en Inglés | MEDLINE | ID: mdl-24695740

14.

Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.

Gu, Xiaorong; Saunthararajah, Yogen.

Br J Haematol ; 189(3): 578-581, 2020 05.

Artículo en Inglés | MEDLINE | ID: mdl-32112392

15.

AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.

Wunderlich, Mark; Mizukawa, Benjamin; Chou, Fu-Sheng; Sexton, Christina; Shrestha, Mahesh; Saunthararajah, Yogen; Mulloy, James C.

Blood ; 121(12): e90-7, 2013 Mar 21.

Artículo en Inglés | MEDLINE | ID: mdl-23349390

16.

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation.

Saunthararajah, Yogen.

Haematologica ; 105(9): 2191-2193, 2020 09 01.

Artículo en Inglés | MEDLINE | ID: mdl-33054042

17.

Polycomb segment myeloid malignancies.

Saunthararajah, Yogen; Maciejewski, Jaroslaw.

Blood ; 119(5): 1097-8, 2012 Feb 02.

Artículo en Inglés | MEDLINE | ID: mdl-22308277

18.

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Lavelle, Donald; Vaitkus, Kestis; Ling, Yonghua; Ruiz, Maria A; Mahfouz, Reda; Ng, Kwok Peng; Negrotto, Soledad; Smith, Nicola; Terse, Pramod; Engelke, Kory J; Covey, Joseph; Chan, Kenneth K; Desimone, Joseph; Saunthararajah, Yogen.

Blood ; 119(5): 1240-7, 2012 Feb 02.

Artículo en Inglés | MEDLINE | ID: mdl-22160381

19.

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Visconte, Valeria; Rogers, Heesun J; Singh, Jarnail; Barnard, John; Bupathi, Manoj; Traina, Fabiola; McMahon, James; Makishima, Hideki; Szpurka, Hadrian; Jankowska, Anna; Jerez, Andres; Sekeres, Mikkael A; Saunthararajah, Yogen; Advani, Anjali S; Copelan, Edward; Koseki, Haruhiko; Isono, Kyoichi; Padgett, Richard A; Osman, Sami; Koide, Kazunori; O'Keefe, Christine; Maciejewski, Jaroslaw P; Tiu, Ramon V.

Blood ; 120(16): 3173-86, 2012 Oct 18.

Artículo en Inglés | MEDLINE | ID: mdl-22826563

20.

Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.

Boasman, Kristian; Simmonds, Matthew James; Graham, Ciaren; Saunthararajah, Yogen; Rinaldi, Ciro Roberto.

Ann Hematol ; 98(6): 1529-1531, 2019 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-30721335

Portal de Búsqueda de la BVS Ecuador

Información y Conocimiento para la Salud

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders.

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.

Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.

Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas.

OAS-RNase L innate immune pathway mediates the cytotoxicity of a DNA-demethylating drug.

Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.

Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse.

Targeting sickle cell disease root-cause pathophysiology with small molecules.

ß-Hemoglobinopathies lead the way.

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice.

The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis).

Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy.

Cytoplasmic dislocation of NPM1 and PU.1 in NPM1-mutated leukaemia is obscured by paraformaldehyde fixation.

AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model.

Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation.

Polycomb segment myeloid malignancies.

Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Using PU.1 and Jun dimerization protein 2 transcription factor expression in myelodysplastic syndromes to predict treatment response and leukaemia transformation.